Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 26, 2007

Goodwin Biotechnology to Produce Neogenix’ mAb for Pancreatic Cancer

  • Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.

    Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »